5-phenyl-thiazol-2-yl-urea derivatives and use as pi3 kinase inhibitors

Details for Australian Patent Application No. 2007253614 (hide)

Owner Novartis AG

Inventors Fox Hayler, Judy; Cox, Brian; Legrand, Darren Mark Novartis Horsham Research Centre; Budd, Emma; Ian, Bruce

Agent Davies Collison Cave

Pub. Number AU-A-2007253614

PCT Pub. Number WO2007/134827

Priority 0610243.8 23.05.06 GB

Filing date 21 May 2007

Wipo publication date 29 November 2007

International Classifications

C07D 277/48 (2006.01) Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings

A61K 31/427 (2006.01) - not condensed and containing further heterocyclic rings

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

C07D 417/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

20 November 2008 PCT application entered the National Phase

  PCT publication WO2007/134827 Priority application(s): WO2007/134827

1 March 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007253615-Pyrazolo [3, 4-d] pyrimidine derivatives useful to treat respiratory disorders

2007253613-Self-compensating drift-free radiofrequency phase detector circuit